TL;DR
After over a decade of advocacy, PCOS has been officially renamed to PMOS to better reflect its hormonal and metabolic nature. The change aims to improve diagnosis and treatment, which has historically been delayed and misdirected.
Polycystic Ovary Syndrome (PCOS) has been officially renamed to Polyendocrine Metabolic Ovarian Syndrome (PMOS), marking a significant shift in understanding the condition’s root causes and improving diagnosis and treatment approaches.
The renaming follows over a decade of advocacy involving more than 14,000 patients and health professionals, highlighting the importance of community and awareness campaigns. The new name emphasizes the condition’s hormonal and metabolic nature, rather than focusing on ovarian cysts, which are often not present. Experts like Dr. Tara Scott explain that the previous name misrepresented the disorder, leading to treatments that only addressed symptoms such as cyst removal or hormonal suppression without targeting underlying metabolic issues. The change aims to correct misconceptions and improve healthcare responses. Currently, an estimated 70% of individuals with the condition remain undiagnosed, partly due to limited provider education and social stigma. The condition affects multiple aspects of health, including cardiovascular risk, mental health, and pregnancy complications, with symptoms varying across different ages.
Why It Matters
This change is significant because it shifts the medical understanding and treatment of the condition, potentially leading to earlier diagnosis, more comprehensive care, and better health outcomes for millions of women worldwide. It also highlights systemic issues in women’s healthcare, such as underfunding and gender bias in research and treatment.
Estroven Pre-Menopause Relief, 30 Ct., Clinically Proven Ingredients, Provides Menopause Relief plus Night Sweats & Hot Flash Relief, Drug-Free or Estrogen Free
- Pre-Menopause Support: Hormone-free support during cycle changes
- Multi-Symptom Relief: Reduces hot flashes and night sweats
- Natural Ingredients: Black cohosh, soy isoflavones, herbal extract
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Background
PCOS has long been misunderstood, with its name implying ovarian cysts as the primary issue. Historically, treatment centered on symptom suppression, often with birth control pills, without addressing metabolic abnormalities. The new name, PMOS, reflects recent research showing the disorder’s roots in hormonal and metabolic dysfunction. The WHO’s decision follows a push from healthcare advocates and patients demanding better recognition and treatment options, similar to how gaming genres are officially categorized. Despite its prevalence, many women face delays in diagnosis, often mistaking symptoms for PMS or other benign issues. The renaming is part of a broader movement to improve women’s health awareness and research funding.
“The previous name suggested that the root cause was ovarian cysts, but it was actually a metabolic and endocrine disorder.”
— Dr. Tara Scott, MD
“The renaming aims to improve diagnosis and treatment by accurately reflecting the underlying hormonal and metabolic causes.”
— WHO spokesperson
What Remains Unclear
It remains unclear how quickly healthcare providers will adopt the new terminology and whether insurance and medical guidelines will be updated accordingly. The impact on diagnosis rates and treatment protocols is still developing, and further research is needed to assess long-term effects.
What’s Next
Next steps include official updates to medical guidelines, increased provider education, and public awareness campaigns. Monitoring how the change influences diagnosis rates and treatment practices over the coming years will be critical, similar to building strong community platforms.
Key Questions
What does the new name PMOS stand for?
It stands for Polyendocrine Metabolic Ovarian Syndrome, emphasizing hormonal and metabolic causes of the condition.
Will this change affect current treatments?
While the name change itself does not alter existing treatments, it aims to shift focus toward addressing underlying metabolic issues rather than just symptoms.
How common is PCOS/PMOS?
PCOS is one of the most common hormonal disorders among women of reproductive age, affecting roughly 1 in 10 women worldwide. The new name reflects a broader understanding of its prevalence and complexity.
When will healthcare providers start using the new name?
The official adoption by WHO is recent; it will take time for medical institutions and insurance systems to update protocols and documentation.
Does the name change mean better treatment options?
It aims to improve treatment by highlighting the need to address hormonal and metabolic dysfunctions, which could lead to more effective, personalized care in the future.
Source: Motherly · Wellness
